Dr. Maziarz has been involved in clinical investigation and translational research, for over four decades, beginning with research and clinical training at the Dana-Farber Cancer Institute and the Brigham & Women’s Hospital. He moved to OHSU in 1991 to develop a transplantation immunology program and serve as the Founding medical director of the adult OHSU stem cell transplant program. His research involves the immunology of transplantation or its complications, particularly in studying the immunopathophysiology of GVHD. He has served as principal investigator or co- investigator on over 150 clinical trials and involved with multiple initiatives sponsored by numerous national transplant organizations including SWOG, CIBMTR, ISCT, NMDP and BMT CTN. A special interest has been the intersection of transplantation and health policy. He served as consultant to the Oregon Health Resource Commission assessing indications for autologous transplantation and analyzing efficacy of reduced intensity allogeneic transplantation as a standard of care for adults with hematologic malignancies and been an active member of the Health Policy working committee of the CIBMTR, a member of the ASBMT reimbursement committee and served as Chair of the NMDP financial working group for their system capacity & Chair of the Health Economics SIG for ASBMT. Most recently, he has been a member of HRSA Advisory Group on Blood Stem Cell Transplantation where I serve as Chair, Drug Shortage Committee.
At OHSU, he maintained a laboratory focused on basic and preclinical models focused on how to reduce the risks for morbidity and mortality associated with graft versus host disease, and actively mentor multiple preclinical and clinical trainees. Most recently, focus has been on the toxicity and efficacy of immune effector cell therapy. He has served on multiple IEC trials, assisted the generation/ writing of new emerging trials utilizing CART and NK cells for various disease indications and served as the Chair, Scientific Steering Committee for the Juliet trial that led to the FDA approval of tisagenlecleucel for advanced diffuse large B cell lymphoma. Other recent initiatives include a collaborative translational and clinical training program in HCT/CT for Bangkok Hospital in Thailand as they expand services to their country’s residents.